Every 8-K that PAVmed Inc. (PAVM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PAVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAVM filings page.
PAVmed Inc. (PAVM) entered into a Sales Agreement with A.G.P./Alliance Global Partners to establish an “at the market offering” program for its common stock. Under this arrangement, PAVmed may offer and sell, from time to time through or to the agent, up to $9,400,000 of common shares pursuant to its existing shelf registration statement on Form S-3.
The company will pay the agent a 3.0% commission on aggregate gross sales of shares and reimburse specified legal fees, including up to $65,000 at execution, quarterly amounts thereafter, and additional fees for program refreshes. Either party may terminate the agreement with ten business days’ written notice, and PAVmed states that net proceeds are intended for working capital and general corporate purposes.
PAVmed Inc. reported second-quarter 2026 results and a business update across its Lucid Diagnostics, Veris Health, and Octeris subsidiaries. Veris increased patient onboarding at OSU-The James and advanced development of its implantable physiological monitor toward an early 2027 FDA 510(k) submission, with design freeze nearing completion and successful manufacturing test runs. Lucid recognized $1.5 million in EsoGuard Esophageal DNA Test revenue in 2Q26 on 2,770 processed tests and secured its first laboratory benefit manager coverage policy for EsoGuard, already adopted by multiple health plans.
PAVmed’s revenue for the quarter ended June 30, 2026 was $33 thousand, compared with $6 thousand a year earlier. Total operating expenses were $7.1 million versus $4.7 million in 2Q25. Net loss as reported attributable to common stockholders was $5.4 million, with diluted loss per share of $0.87. EBITDA was a loss of $5.6 million, and non-GAAP adjusted loss was $1.7 million, or $0.27 per basic and diluted share.
PortIO first-in-human results were published, showing 100% device patency, 90% completion of intended implant duration, and no device-related adverse events, while Octeris advanced its multimodal endoscopic imaging probe toward clinical validation.
PAVmed Inc. reported results of its annual stockholder meeting. Stockholders representing approximately 59.6% of shares outstanding and entitled to vote participated in person or by proxy. Management’s nominees Ronald M. Sparks and Timothy Baxter were re-elected as Class A directors.
Stockholders approved amendments to the Employee Stock Purchase Plan, increasing the total shares available from 15,774 to 215,774 and raising the annual limit on automatic share increases from 5,556 to 500,000. They also ratified CBIZ CPAs P.C. as the independent registered certified public accounting firm for the year ending December 31, 2026.
PAVmed Inc. reported first quarter 2026 results and a broad business update across its medical device, diagnostics, and digital health businesses. Revenue was $22 thousand, while operating expenses were about $8.1 million, leading to a GAAP net loss attributable to common stockholders of roughly $7.0 million, or $(4.42) per diluted share.
On a non-GAAP basis, PAVmed reported an adjusted loss of about $1.9 million, or $(1.17) per share. Cash and cash equivalents were $6.5 million as of March 31, 2026, up from $1.5 million at year-end 2025. Subsidiary Lucid Diagnostics recognized $1.3 million in EsoGuard test revenue, processed 3,177 tests, raised approximately $17 million through an underwritten offering, and ended the quarter with $45 million in pro forma cash, extending its runway into 2027.
Management highlighted Veris Health’s progress toward an FDA 510(k) submission for its implantable physiological monitor and deeper commercial engagement with The Ohio State University’s James Cancer Hospital. PAVmed also emphasized its simplified capital structure, strengthened balance sheet, and the advancement of its relaunched medical device portfolio, including the PortIO vascular access device and endoscopic esophageal imaging technology.
PAVmed Inc. reported fourth quarter and full year 2025 results and detailed major balance sheet and business changes. For the three months ended December 31, 2025, revenue was $52,000, operating expenses were about $6.9 million, and GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per diluted share. Non-GAAP adjusted loss was about $0.9 million, or $(1.05) per share.
The company raised $30 million through a Series D preferred stock offering and $15 million via senior secured notes, using part of the proceeds to eliminate all previously outstanding convertible securities and extend its cash runway. It also issued $30 million in Series D warrants linked to a draft CMS coverage policy for Lucid’s EsoGuard test, reported cash and cash equivalents of $1.5 million as of December 31, 2025, and highlighted progress at subsidiaries Lucid Diagnostics and Veris Health, including a VA contract for EsoGuard, large real-world data on esophageal precancer detection, and advancement of an implantable physiological monitor toward a planned late 2026 FDA 510(k) submission.
PAVmed Inc. held a special stockholder meeting where approximately 54.1% of voting power was represented. Stockholders approved issuances of common stock for Nasdaq Listing Rule 5635 purposes related to 60,000 shares of Series D Convertible Preferred Stock and an Amended and Restated Senior Secured Convertible Note.
They also approved an amendment to the certificate of incorporation to allow removal of any director, with or without cause, by a majority of the company’s outstanding voting power. In addition, stockholders approved an amendment to the 2014 Long-Term Incentive Equity Plan to increase the share pool by 1,500,000 shares, from 213,517 to 1,713,517.
PAVmed Inc. entered subscription agreements with accredited investors to raise $30 million by selling 30,000 shares of new Series D Convertible Preferred Stock and issuing warrants to buy an additional 30,000 Series D shares at $1,000 per share.
The Series D Preferred Stock initially converts into common stock at $6.50 per share, with conversion and voting limited by ownership caps and Nasdaq’s 19.99% market limit until stockholder approval. PAVmed plans a special stockholder meeting by April 30, 2026, and investors holding over 20% of common stock agreed to support the approval.
Concurrently, the company redeemed all 16,962 Series C Preferred shares and refinanced $8,414,890 of its 2022 convertible note into a new secured 2026 Note with $15 million principal, a 15% cash interest rate, and strong covenants, including minimum cash requirements and tests linked to the value of PAVmed’s Lucid Diagnostics stake.
PAVmed Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq’s Listing Qualifications department notified the company on January 21, 2026 that its common stock now meets the $1 per share minimum bid price required under Nasdaq Listing Rule 5550(a)(2).
The company had previously been notified on January 23, 2025 that its stock had closed below $1 per share for 30 consecutive business days through January 22, 2025. Nasdaq has since determined that from January 2, 2026 to January 19, 2026, the closing bid price of PAVmed’s common stock was at or above $1 per share, bringing the company back into compliance and reducing the immediate risk of delisting from the Nasdaq Capital Market.
PAVmed Inc. filed an 8-K stating it furnished a press release with financial results for the fiscal quarter ended September 30, 2025, along with a business update. The disclosure was provided under Items 2.02 and 7.01 and is designated as furnished, not filed, under the Exchange Act. The full press release is included as Exhibit 99.1.